사실 자료: 도널드 제이 트럼프 수반, 처방약 가격 인하 조치 발표

LOWERING PRESCRIPTION DRUG PRICES: Today, President Donald J. Trump signed an Executive Order to expand on the historic efforts of his first term to lower prescription drug prices.

- The Order directs the Department of Health and Human Services to take steps to significantly reduce drug prices for American patients.

- It delivers lower drug prices for Medicare and the seniors who rely on it by:

Improving the Medicare Drug Pricing Negotiation Program in order to eclipse the 22% in savings achieved in the program’s first year.

Aligning Medicare payment for certain prescription drugs with the cost by which hospitals actually acquire them, which can be 35% lower than what the government currently pays.

Standardizing Medicare payments for prescription drugs, such as cancer treatments, regardless of where the patient receives care, which can lower prices by as much as 60%.

- Improving the Medicare Drug Pricing Negotiation Program in order to eclipse the 22% in savings achieved in the program’s first year.

- Aligning Medicare payment for certain prescription drugs with the cost by which hospitals actually acquire them, which can be 35% lower than what the government currently pays.

- Standardizing Medicare payments for prescription drugs, such as cancer treatments, regardless of where the patient receives care, which can lower prices by as much as 60%.

- It provides massive discounts to low-income patients for life-saving medications.

Insulin prices for low-income patients and the uninsured will be lowered to as low as $0.03, plus a small administrative fee.

Injectable epinephrine for low-income patients and the uninsured will be as low as $15, plus a small administrative fee.

- Insulin prices for low-income patients and the uninsured will be lowered to as low as $0.03, plus a small administrative fee.

- Injectable epinephrine for low-income patients and the uninsured will be as low as $15, plus a small administrative fee.

- The Order helps states reduce drug prices by:

Facilitating importation programs that could save states millions in prescription drug costs.

Building off programs to help states get much better deals on expensive sickle-cell medications in Medicaid than the statutorily required 23.1% discount.

- Facilitating importation programs that could save states millions in prescription drug costs.

- Building off programs to help states get much better deals on expensive sickle-cell medications in Medicaid than the statutorily required 23.1% discount.

BRINGING RADICAL TRANSPARENCY AND COMPETITION TO PRESCRIPTION DRUG MARKETS: President Trump is dedicated to creating a transparent, competitive, and fair prescription drug market for American consumers.

- President Trump has already taken numerous actions to end the practice of large corporations profiting by keeping health care prices and business practices hidden from Americans.

- The Order increases the availability of generics and biosimilars, which can be as much as 80% cheaper than brand alternatives.

- The Order builds off that critical work and reevaluates the role of middlemen by:

Improving disclosure of fees that pharmaceutical benefit managers (PBMs) pay to brokers for steering employers to utilize their services.

Directing the administration to develop reforms to promote a more competitive, transparent, efficient, and resilient prescription drug value chain.

- Improving disclosure of fees that pharmaceutical benefit managers (PBMs) pay to brokers for steering employers to utilize their services.

- Directing the administration to develop reforms to promote a more competitive, transparent, efficient, and resilient prescription drug value chain.

- By addressing the influence of middlemen and promoting open competition, President Trump’s actions aim to create a fairer prescription drug market that lowers costs and ensures accountability across the health care system.

PUTTING AMERICAN PATIENTS FIRST ONCE AGAIN: President Trump is delivering on his promise to once again put American patients first by building off of the historic efforts of his first term to lower prescription drug prices.

- In his first term, President Trump took numerous actions that delivered real results for patients:

The Food and Drug Administration sped up development of lower-cost generic medicines and biosimilars as well as created a pathway for states to import lower cost drugs from Canada.

Government-mandated discounts were passed through to patients instead of being retained by middlemen.

Price transparency rules were developed to allow patients, doctors, and employers to see the actual cost of prescription drugs.

Insulin copays were capped for Medicare beneficiaries.

- The Food and Drug Administration sped up development of lower-cost generic medicines and biosimilars as well as created a pathway for states to import lower cost drugs from Canada.

- Government-mandated discounts were passed through to patients instead of being retained by middlemen.

- Price transparency rules were developed to allow patients, doctors, and employers to see the actual cost of prescription drugs.

- Insulin copays were capped for Medicare beneficiaries.

- Unsurprisingly, the Biden-Harris Administration let many of these priorities languish while failing to even achieve the savings projected from the new Medicare Prescription Drug Negotiation Program.

- President Trump will not stand for inaction, and his Administration is working rapidly to lower the cost of prescription drugs for Americans.